Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407324 · ClinicalTrials.gov registry record · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
- 20
- Study locations
NCT05407324 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 279 participants, below the 895-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05407324, a Phase 2 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dazucorilant 300 mg
- DRUG Dazucorilant 150 mg
- DRUG Dazucorilant
Study Locations (20)
Other
- 108 - Leuven
- 422 - Bron
- 258 - Lille
- 257 - Limoges
- 261 - Marseille
- 423 - Montpellier
- 259 - Nice
- 262 - Paris
- 256 - Tours
- 255 - Berlin
- 270 - Bonn
- 268 - Dresden
- 260 - Hanover
- 265 - Jena
Arizona
- 062 - Phoenix
California
- 278 - San Francisco
New Jersey
- 287 - Neptune City
New York
- 353 - New York
Ontario
- 425 - Hamilton
Quebec
- 273 - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05407324
The ClinicalTrials.gov registry entry for NCT05407324 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 895-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (69% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05407324 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05407324 about?
NCT05407324 is a clinical study titled "Dazucorilant in Patients With Amyotrophic Lateral Sclerosis". The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
What is the current status of trial NCT05407324?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2022-11-15. Estimated completion is 2027-11.
What conditions does trial NCT05407324 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05407324?
The interventions under investigation include: Placebo (OTHER), Dazucorilant 300 mg (DRUG), Dazucorilant 150 mg (DRUG), Dazucorilant (DRUG).
Who is sponsoring clinical trial NCT05407324?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05407324 being conducted?
This trial has 20 study locations across Arizona, California, New Jersey, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.